KU Leuven logo

KU Leuven

Europe, Vlaams-Brabant, Belgium, Leuven

Description

Founded in 1425, the multidisciplinary and research-driven University of Leuven has been a centre of learning for almost six centuries.

Investor Profile

KU Leuven has made 12 investments, with 0 in the past 12 months and 17% as lead.

Stage Focus

  • Seed (42%)
  • Series B (33%)
  • Series A (25%)

Country Focus

  • Belgium (83%)
  • Ireland (8%)
  • Brazil (8%)

Industry Focus

  • Biotechnology
  • Medical
  • Manufacturing
  • Clinical Trials
  • Pharmaceutical
  • Therapeutics
  • Medical Device
  • Hospital
  • Analytics
  • Data Management
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does KU Leuven frequently co-invest with?

BNP Paribas Fortis
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 2
Gemma Frisius Fund
Europe, Vlaams-Brabant, Belgium, Leuven
Co-Investments: 5
VIB
Europe, Oost-Vlaanderen, Belgium, Gent
Co-Investments: 2
Limburgse Reconversie Maatschappij
Europe, Limburg, Belgium, Hasselt
Co-Investments: 1
Korys
Europe, Vlaams-Brabant, Belgium, Halle
Co-Investments: 2
F
North America, Florida, United States, Boca Raton
Co-Investments: 1
Meusinvest (Noshaq)
Europe, Liege, Belgium, Liège
Co-Investments: 2
SoFi
North America, California, United States, San Francisco
Co-Investments: 2
imec
Europe, Vlaams-Brabant, Belgium, Leuven
Co-Investments: 1
PMV
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Co-Investments: 4

Which angels does KU Leuven often collaborate with?

BM
Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels
Shared Deals: 1
AV
Europe, Antwerpen, Belgium, Antwerp
Shared Deals: 1
CW
Europe, Vlaams-Brabant, Belgium, Leuven
Shared Deals: 1
Shared Deals: 1

What are some of recent deals done by KU Leuven?

Imcyse

Liège, Liege, Belgium

Developing disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors.

BiotechnologyPharmaceuticalTherapeutics
Series BFeb 17, 2021
Amount Raised: $25,659,559
reMYND

Leuven, Vlaams-Brabant, Belgium

reMYND drives the development of disease-modifying treatments against protein misfolding disorders.

BiotechnologyClinical TrialsManufacturingMedical
Series BJan 21, 2021
Amount Raised: $14,598,682
Virovet

Leuven, Vlaams-Brabant, Belgium

ViroVet is a pioneering company.

BiotechnologyPharmaceuticalVeterinary
Series BMay 28, 2020
Amount Raised: $6,647,249
Montis Biosciences

Meise, Vlaams-Brabant, Belgium

Montis Biosciences is develops novel immune-oncology therapeutics targeting the intersection between vascular dysfunction.

BiotechnologyOncologyTherapeutics
SeedFeb 20, 2020
Amount Raised: $9,061,714
Pulsify Medical

Leuven, Vlaams-Brabant, Belgium

Pulsify Medical is a digital medical technology company that provides ultrasound monitoring patches for patients.

MedicalMedical Device
SeedOct 15, 2019
Amount Raised: $2,868,709
MyCellHub

Leuven, Vlaams-Brabant, Belgium

MyCellHub.com - Data management and process analytics for manufacturers of cell-based products.

AnalyticsData ManagementManufacturing
SeedSep 12, 2019
Amount Raised: $1,216,197
nextAuth

Leuven, Vlaams-Brabant, Belgium

nextAuth provides strong multi-factor authentication combined with an almost-seamless user experience.

Cyber Security
SeedMar 18, 2019
reMYND

Leuven, Vlaams-Brabant, Belgium

reMYND drives the development of disease-modifying treatments against protein misfolding disorders.

BiotechnologyClinical TrialsManufacturingMedical
Series BDec 18, 2018
Amount Raised: $13,651,023
Loci Orthopaedics

Galway, Galway, Ireland

A innovative orthopaedic implant for the treatment of thumb base arthritis.

BiotechnologyLife ScienceMedical Device
SeedJul 7, 2018
Amount Raised: $3,232,214
UgenTec

Hasselt, Limburg, Belgium

UgenTec delivers an independent diagnostic platform to help molecular labs with their DNA (PCR) analyses.

BiotechnologyHospitalMedical
Series AMar 29, 2018
Amount Raised: $9,226,817